Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial-mesenchymal transition biomarkers

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 47-54

  Tai, Cheng Jeng ^a,b   Cheng, Chao Wen ^c   Su, Hou Yu ^d   Chen, Wei Yu ^e   Wu, Chun Te ^f,g   Lin, Feng Yen ^a,b   Wang, Chien Kai ^a,b   Tai, Chen Jei ^a,b   Wei, Po Li ^a,c  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Camillian Saint Mary's Hospital Luodong   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cervical cancer; EMT; Migration; Thrombomodulin

Indexed keywords

BIOLOGICAL MARKER; THROMBOMODULIN; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN;

ARTICLE; BIOSENSOR; CANCER CELL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GROWTH RATE; HELA CELL; HUMAN; HUMAN CELL; MTT ASSAY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER;

BIOLOGICAL MARKERS; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE SILENCING; HELA CELLS; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; THROMBOMODULIN; UTERINE CERVICAL NEOPLASMS;

EID: 84893732359     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1005-7     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;27:2893-917
2. Tavassoli FA, Devilee P. World Health Organization., International Agency for Research on Cancer: Pathology and genetics of tumours of the breast and female genital organs. Lyon, IARC, 2003.
3. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749-57.
4. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535-40.
5. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781-6.
6. Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys. 2011;79:325-34.
7. del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol. 2008;110:S72-76.
8. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973-81.
9. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131-42.
10. Murakami A, Nakagawa T, Fukushima C, Torii M, Sueoka K, Nawata S, et al. Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. Oncol Rep. 2008;19:99-104.
11. Esmon CT. The roles of protein c and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743-6.
12. Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M. Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays. Dev Biol. 1990;140:113-22.
13. Hanly AM, Winter DC. The role of thrombomodulin in malignancy. Semin Thromb Hemost. 2007;33:673-9.
14. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood. 2008;112:3661-70.
15. Tezuka Y, Yonezawa S, Maruyama I, Matsushita Y, Shimizu T, Obama H, et al. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res. 1995;55:4196-200.
16. Kim SJ, Shiba E, Ishii H, Inoue T, Taguchi T, Tanji Y, et al. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study. Anticancer Res. 1997;17:2319-23.
17. Liu PL, Tsai JR, Chiu CC, Hwang JJ, Chou SH, Wang CK, et al. Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer. Mol Carcinog. 2010;49:874-81.
18. Hanly AM, Redmond M, Winter DC, Brophy S, Deasy JM, Bouchier-Hayes DJ, et al. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer. 2006;94:1320-5.
19. Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology. 1995;21:1285-90.
20. Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, et al. Knockdown of thrombomodulin enhances HCC cell migration through increase of zeb1 and decrease of E-cadherin gene expression. Ann Surg Oncol. 2010;17:3379-85.
21. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-sign. Proc Natl Acad Sci U S A. 2008;105:3690-5.
22. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol. 2008;10:211-9.
23. Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603-12.
24. Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703-9.
25. Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone GRP78/BIP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008;68:498-505.
26. Wei PL, Kuo LJ, Huang MT, Ting WC, Ho YS, Wang W, An J, Chang YJ. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann Surg Oncol. 2011;18:1782-90
27. Lien YC, Wang W, Kuo LJ, Liu JJ, Wei PL, Ho YS, Ting WC, Wu CH, Chang YJ. Nicotine promotes cell migration through alpha7 nicotinic acetylcholine receptor in gastric cancer cells. Ann Surg Oncol. 2011;18:2671-9
28. Wang L, Wang Q, Li HL, Han LY. Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma - relationship with prognosis. Asian Pac J Cancer Prev. 2013;14:2113-8.
29. Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333-59.
30. Bast Jr RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22 Suppl 8:viii5-viii15.
31. Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S116-130.
32. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-54.
33. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72:1878-89.
34. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31:4619-29
35. Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol. 1997;28:922-8.
36. Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer. 1994;58:393-9.
37. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, et al. Emt transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12:91.
38. Hsu YM, Chen YF, Chou CY, Tang MJ, Chen JH, Wilkins RJ, et al. Kcl cotransporter-3 down-regulates E-cadherin/beta-catenin complex to promote epithelial-mesenchymal transition. Cancer Res. 2007;67:11064-73.
39. Cheng Y, Zhou Y, Jiang W, Yang X, Zhu J, Feng D, et al. Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma. Hum Pathol. 2012;43:1213-20.
40. Myong NH. Loss of E-cadherin and acquisition of vimentin in epithelial-mesenchymal transition are noble indicators of uterine cervix cancer progression. Korean journal of pathology. 2012;46:341-8.
41. Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008;21:912-23.
42. Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, et al. The transcription factor zeb1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006;66:3893-902.
43. Kao YC, Wu LW, Shi CS, Chu CH, Huang CW, Kuo CP, et al. Downregulation of thrombomodulin, a novel target of snail, induces tumorigenesis through epithelial-mesenchymal transition. Mol Cell Biol. 2010;30:4767-85.